Teva Pharmaceutical partners with Fosun Pharma to develop TEV-56278, an anti-PD1-IL2 therapy using ATTENUKINE technology. The collaboration aims to advance cancer treatment globally with low toxicity. Fosun Pharma will have exclusive rights in certain regions.